baber/WOPTO huggingface dataset:
Patent NZ-588554-A (NZ)
Title: Dual variable domain immunoglobulins and uses thereof
Inventor: GHAYUR TARIQ
IPC: A61K39/00
Filed: 2009-04-28
Abstract: Disclosed is a binding protein comprising first and second polypeptide chains, each independently comprising VD1-(X1)n-VD2-C-(X2)n, wherein VD1 is a first variable domain; VD2 is a second variable domain; C is a constant domain; X1 is a linker with the proviso that it is not CH1; X2 is an Fc region; n is 0 or 1. Furthermore, the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site and are as defined in the specification. The disclosed binding protein is capable of binding to VEGF with an EC50 of at most about 28.25 nM, as measured by direct bind ELISA, and/or the binding protein is capable of binding to DLL4 with an EC50 of at most about 2.12nM, as measured by direct bind ELISA.
Patent NZ-590399-A (NZ)
Title: Device, system, and method for treating psychiatric disorders
Inventor: CARTREINE JAMES ALBERT
IPC: A61B5/16
Filed: 2009-07-10
Abstract: 606306 Disclosed is a system for treating a patient (65) having a psychiatric disorder. The system has a memory which configures a processor. The processor records an event experienced being recounted by the patient (65). The event is parsed into a plurality of stimuli for subsequent playback to the patient 65) and a mental state metric is generated for each of the one or more stimuli. Each mental state metric is indicative of a mental state of the patient (65) at a time when an associated stimulus was being recounted. A sensory environment of the patient (65) is controlled so as to administer exposure therapy by causing a selected one of the stimuli to be played back to the patient (65) one or more times. A mental state of the patient (65) is monitored as the selected is played back one or more times during administration of the exposure therapy to the patient (65). The exposure therapy that is administered to the patient (65) is varied in correspondence to the monitored mental state by selecting a different one of the stimuli for subsequent play back on the monitored mental state of the patient.
Patent NZ-592930-A (NZ)
Title: Arylcyclopropylacetamide derivatives useful as glucokinase activators
Inventor: BUENO MELENDO ANA BELEN
IPC: A61P3/10
Filed: 2009-12-11
Abstract: Patent: 592930 Disclosed herein is a compound of the given formula, particularly (1R,2S)-2-Cyclohexyl-1-(4-cyclopropanesulfonyl-phenyl)-cyclopropanecarboxylic acid [5-(2-pyrrolidin-1-yl-ethylsulfanyl)-thiazol-2-yl]-amide, processes for its preparation, compositions comprising said compounds and uses thereof. Said compounds are useful in the treatment of diabetes, particularly type II diabetes.
Patent NZ-593849-A (NZ)
Title: Methods to treat cancer
Inventor: LAVOIE EDMOND J
IPC: A61K35/00
Filed: 2010-01-29
Abstract: 593849 Disclosed is a non-camptothecin topoisomerase I inhibitor of formula 3 for treating cancers.
Patent NZ-595615-A (NZ)
Title: Combination therapy against cancer utilising 3-beta-cholestanyl-3-O-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-beta-D-galactopyranoside and is derivatives
Inventor: YAZAWA SHIN
IPC: A61K33/243
Filed: 2009-03-04
Abstract: 595615 Disclosed is the use of a cholestanol derivative represented by formula (I): wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-; or a cyclodextrin inclusion compound thereof, and an anti-cancer agent (such as a metabolism antagonist, a taxane, a platinum complex, a plant alkaloid, or an alkylating agent; including compounds such as pemetrexed compound, 5-fluorouraciI, Paclitaxel, Docetaxcel, Alimta, Cisplatin, Oxaliplatin or Cyclophosphamide) in independent and separate doses formulated for separate or simultaneous combined administration, wherein said anti-cancer agent is not lidocaine or procaine, in a kit for the preparation of a medicament for the treatment of cancer.
Patent NZ-596164-A (NZ)
Title: Cellulosic and lignocellulosic structural materials and methods and systems for manufacturing such materials by irradiation
Inventor: MEDOFF MARSHALL
IPC: B32B21/14
Filed: 2009-04-28
Abstract: Disclosed is a method of treating wood, the method comprising: irradiating untreated wood having a first molecular weight with electron beam radiation while controlling a gas blanketing the wood through which the electron beam passes, electrons of the beam having an energy of about 2.5 to about 10 MeV, to increase the molecular weight of a cellulosic component of the wood to a second, relatively higher molecular weight at least about 10 percent higher than the first weight. A wood product formed by this method is also disclosed.
Patent NZ-601519-A (NZ)
Title: COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS INFECTION comprising lamivudine and adefovir dipivoxil
Inventor: Zhou xiao-jian
IPC: A61K31/506
Filed: 2010-12-30
Abstract: 601519 Disclosed is a pharmaceutical composition for treating hepatitis B virus infection in a human, comprising: a first active pharmaceutical ingredient consisting of more than 400 mg to about 1500 mg of lamivudine, (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one, or a therapeutically equivalent amount of a pharmaceutically acceptable salt or ester thereof; and a second active pharmaceutical ingredient consisting of about 1 mg to about 10 mg of adefovir dipivoxil, bis(pivaloyloxymethyl)(9-[(R)-2(phosphonomethoxy)ethyl] adenine, or a therapeutically equivalent amount of a pharmaceutically acceptable salt or ester thereof.
Patent NZ-602020-A (NZ)
Title: Anti-cd40 antibodies
Inventor: BARRETT RACHEL
IPC: A61K39/395
Filed: 2011-03-30
Abstract: Disclosed is a humanized CD40 binding antibody, wherein said antibody comprises a heavy chain CDR1 sequence of SEQ ID NO: 11, a heavy chain CDR2 sequence of SEQ ID NO:15 and a heavy chain CDR3 sequence of SEQ ID NO:17; and wherein said antibody comprises a light chain CDR1 sequence of SEQ ID NO:21, a light chain CDR2 sequence of SEQ ID NO:23 and a light chain CDR3 sequence of SEQ ID NO:25. Further disclosed are antibodies comprising said CDR regions and uses thereof ffor treating CD40 mediated immune response diseases or disorders. SEQ ID NO: 11 GFTFSDYGMH SEQ ID NO: 15 YISSGNRIIYYADTVKG SEQ ID NO: 17 QDGYRYAMDY SEQ ID NO: 21 KSSQSLLNSGNQKNYLT SEQ ID NO: 23 WTSTRES SEQ ID NO: 25 QNDYTYPLT
Patent NZ-604034-A (NZ)
Title: New medium, devices and methods
Inventor: AXELSSON JONAS
IPC: C07K17/02
Filed: 2011-06-17
Abstract: NZ 604034 Disclosed is a method for extracorporeal removal of a low molecular weight protein, or fragment or derivative thereof, having a megalin and/or cubilin binding motif, from a complex biological fluid, comprising performing the following steps to a sample of complex biological fluid containing a low molecular weight protein, or fragment or derivative thereof, having a binding affinity for megalin and/or cubilin: bringing said sample into contact with one or more of: a separation medium comprising: at least one megalin polypeptide and at least one cubilin polypeptide immobilised on a support; a medical device comprising said separation medium; and a dialysis device comprising said medical device, under conditions allowing binding of said low molecular weight protein, or fragment or derivative thereof, to said at least one megalin polypeptide and/or said at least one cubilin polypeptide, separating said sample from said support, such that at least part of the total amount of said low molecular weight protein, or fragment or derivative thereof, initially present in said sample is retained on the support, and recovering said sample containing a reduced amount of said low molecular weight protein, or fragment or derivative thereof.
Patent NZ-608479-A (NZ)
Title: Synchronous frequency hopping spread spectrum communications
Inventor: SHUEY KENNETH C
IPC: H04W84/18
Filed: 2013-03-20
Abstract: Disclosed is a method for synchronising a receiver with a transmitter in a frequency hopping communication system. In the system, the transmitter and receiver hop through a sequence of predetermined communication frequencies and communicating on each frequency in the sequence for a predetermined period of time before hopping to a next frequency in the sequence. The method includes, at the receiver: scanning at a current frequency and a next frequency of a carrier signal transmitted by the transmitter for a predetermined amount of time before and a predetermined amount of time after each expected hop from the current frequency to the next frequency in the sequence. The method also includes detecting a carrier signal transmitted on the current frequency or the next frequency as a result of the scanning. The method further includes locking on to the carrier signal and continuing to hop in sequence with the transmitter.
Patent NZ-624492-A (NZ)
Title: Technology alternative to money for enabling equitable trade
Inventor: HAY MARTIN ALEXANDER
IPC: G06Q20/00
Filed: 2012-10-17
Abstract: Disclosed is a web-based system for a bartering organisation and users. The system comprises means for creating user agreements between the bartering organisation and the users and means for implementing user agreements between the bartering organisation and the user. The means for implementing user agreements further comprises means for representing chiralkine money; means for representing and operating user accounts in chiralkine money; means for representing monopole property rights; means for representing chiralkine property rights; a web-based bartering market for creating barter transaction agreements between users for monopole property rights or chiralkine property rights in chiralkine money; means for creating credit agreements between the bartering organisation and users subject to a barter transaction agreement, for creating chiralkine money and chiralkine property rights; means for implementing the barter transaction agreements; and means for implementing the credit agreements. The means for implementing the credit agreements further includes means for creating chiralkine money, means for creating chiralkine property rights when the chiralkine money is created, means for destroying chiralkine money, and means for collapsing chiralkine property rights into monopole property rights when the chiralkine money is destroyed.
Patent NZ-624964-A (NZ)
Title: A method for recycling waste thermoplastic materials and using this recycled thermoplastic in composite material production
Inventor: GUVEN ALI HAKAN
IPC: C08J11/06
Filed: 2011-11-10
Abstract: A method for production of thermoplastic composite materials by processing and treating waste plastic materials with particular minerals. The recycling method contains high amounts of additives and therefore composite materials with high strength properties are obtained. The method means the machines used in the production are not damaged.
Patent NZ-626937-A (NZ)
Title: Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors
Inventor: ZHOU CHANGYOU
IPC: C07D495/06
Filed: 2011-12-31
Abstract: Provided are fused tetra or penta-cyclic pyridophthalazinone compounds of the general formula (I), wherein the variables are as defined in the specification. Examples of the compounds include 10,10-Dimethyl-8,9,10,11-tetrahydro-2H-pyridazino[5,4,3-kl]acridin-3(7H)-one and 9-benzyl-8,9,10,11-tetrahydro-2H-phthalazino[8,1-bc][1,7]naphthyridin-3(7H)-one. The compounds are PARP inhibitors. The compounds may be useful in the treatment of cancer, stroke, head trauma and neurodegenerative diseases.
Patent NZ-629045-A (NZ)
Title: Topical compositions comprising fipronil and permethrin and methods of use
Inventor: PATE JAMES
IPC: A61P33/00
Filed: 2013-02-22
Abstract: Disclosed is a topical composition for the treatment and prevention of an ectoparasitic infestation comprising: from about 2 % (w/w) to about 15 % (w/w) fipronil; from about 30 % (w/w) to about 55 % (w/w) permethrin; one or more neutral oils and N-methyl pyrrolidone, wherein said neutral oil and N-methyl pyrrolidone are present in a weight : weight ratio of from about 1:2.0 to about 1:3.5, neutral oil to N-methyl pyrrolidone. The formulation is intended to be storage stable and useful for slowing or preventing the formation of the principal active fipronil metabolite fipronil-sulfone.
Patent NZ-630020-A (NZ)
Title: Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
Inventor: VAUGHN DANIEL EDWARD
IPC: G01N33/574
Filed: 2013-03-08
Abstract: Disclosed is a modified anti-human epidermal growth factor receptor (EGFR) antibody, or antigen-binding fragment thereof, comprising the amino acid replacement Y104D in the variable heavy chain of the unmodified antibody, wherein: the modified anti-EGFR antibody or antigen-binding fragment thereof comprises a variable heavy (VH) chain and a variable light (VL) chain, or a portion thereof that is sufficient to bind EGFR antigen, whereby the VH alone or both the VH and VL is modified; the portion thereof is sufficient to form an antigen binding site and contains the amino acid replacement; the unmodified anti-EGFR antibody is selected from among: i) cetuximab, or an antigen-binding fragment thereof, comprising a variable heavy chain set forth in SEQ ID NO:3 and a variable light chain set forth in SEQ ID NO:4 or 10; ii) a variant of i) comprising a variable heavy chain having a sequence of amino acids that exhibits at least 85% sequence identity to the sequence of amino acids set forth in SEQ ID NO:3, and a variable light chain having a sequence of amino acids that exhibits at least 85% sequence identity to the sequence of amino acids set forth in SEQ ID NO:4 or 10, wherein the variant does not comprise the amino acid replacement and specifically binds to EGFR; and iii) a humanized form of i) or ii); the modified anti-EGFR antibody, or antigen-binding fragment thereof, exhibits a ratio of binding activity to human epidermal growth factor receptor (EGFR) or a soluble fragment thereof under conditions in a tumour environment compared to under conditions in a non-tumour environment of at least 2.0; conditions in a tumour environment comprise one or both of pH between 6.0 to 6.5 or lactate concentration between 5 mM to 20 mM, and protein concentration of 10 mg/mL to 50 mg/mL; and conditions in a non-tumour environment comprise one or both of pH of 7.4 or lactate concentration between 0.5 mM to 5 mM, and protein concentration of 10 mg/mL to 50 mg/mL, whereby the anti-EGFR antibody or fragment thereof is conditionally active under conditions in the tumour microenvironment.
Patent NZ-630831-A (NZ)
Title: Compositions and methods for administration of vaccines against dengue virus
Inventor: STINCHCOMB DAN T
IPC: A61K39/12
Filed: 2013-06-10
Abstract: Disclosed is a method for rapid induction of neutralizing antibodies in a subject against three or more dengue virus serotypes, comprising, subcutaneous administration of two or more doses of a single formulation of a live, attenuated dengue virus vaccine to a subject at two or more anatomical locations on the same day.
Patent NZ-703378-A (NZ)
Title: Degradable clostridial toxins
Inventor: AOKI KEI ROGER
IPC: C07K14/33
Filed: 2011-05-19
Abstract: Disclosed is an isolated Clostridial toxin comprising at least one inactivation cleavage site located within an inactivation cleavage site region, wherein the inactivation cleavage site region is located in the domain comprising amino acids 844-863 of SEQ ID NO:1.
Patent NZ-704219-A (NZ)
Title: Bioprocessing
Inventor: MEDOFF MARSHALL
IPC: C12N11/14
Filed: 2010-05-18
Abstract: A mixture comprising: an inorganic material in the form of particles or fibres and said inorganic material having polar functional groups, a microorganism or enzyme each having complementary functional groups and having an attractive interaction to the functional groups of the inorganic material, a saccharified material, and a solvent, wherein the inorganic material has been functionalized by irradiating the material with ionizing radiation and subsequently quenching the irradiated material with a quenching agent suitable for producing the polar functional groups, and wherein the inorganic material is selected from the group consisting of calcium carbonate, aragonite clay, orthorhombic clays, calcite clay, rhombohedral clays, kaolin, bentonite clay, dicalcium phosphate, tricalcium phosphate, calcium pyrophosphate, insoluble sodium metaphosphate, magnesium orthophosphate, trimagnesium phosphate, hydroxyapatites, synthetic apatites, alumina, hydrated alumina, silica xerogel, metal aluminosilicate complexes, sodium aluminum silicates, zirconium silicate, silicon dioxide, graphite, wollastonite, mica, glass, fiber glass, silica, talc, carbon fibers, conductive carbon black, ceramic powders and ceramic fibers, alumina trihydrate, ground construction waste, and mixtures thereof.
Patent NZ-709741-A (NZ)
Title: Improvement of cognitive function in preterm infants that are small for gestational age
Inventor: VAN ELBURG ROELOF MATTHIJS
IPC: A23L33/00
Filed: 2013-01-09
Abstract: The present invention relates to the use of nutritional compositions enriched in glutamine to improve structural and functional brain development in preterm infants that born small for gestational age.
Patent NZ-717718-A (NZ)
Title: Fertilizer compositions comprising a cellulose nutrient component and methods for using same
Inventor: YAMASHITA THOMAS T
IPC: C05G3/60
Filed: 2015-01-23
Abstract: Aspects of the invention include new compositions which exhibit unexpected potency in fertilizing and remediating soil. Compositions according to certain embodiments are pelletized and include a cellulose nutrient composition, a microbial blend composition, a source of nitrogen, a source of phosphorus, macronutrients comprising potassium, sulfur and calcium, micronutrients comprising zinc, iron and manganese and exotic micronutrients. Methods for using compositions of the invention to fertilize and remediate soil and kits having one or more compositions for fertilizing and remediating soil are also described.
Patent NZ-717799-A (NZ)
Title: Emulsified composition and milk beverage
Inventor: MATSUURA TSUTASHI
IPC: A23C13/14
Filed: 2014-09-11
Abstract: An emulsified composition containing a milk product, an emulsifier, and a magnesium material, wherein the milk product has a total solid content of 20 mass% or above and a ratio of milk fat relative to the total solid content of 30 mass% or above, and the mass ratio of magnesium in relation to the fat content in the composition (fat content: magnesium) is 1:0.0003 to 1:0.01.
Patent NZ-725786-A (NZ)
Title: A pre-formed insert body
Inventor: MORROW CHRISTOPHER CHARLES
IPC: F21V21/04
Filed: 2015-10-30
Abstract: This invention relates to an assembly for defining an aperture in a panel, the assembly comprising of a body (1’) and an insert (101). The insert (101) comprises a front face (6), the front face having at least one reference rim (106). The reference rim extends as a projection of the front face and provides a reference surface (108) to be referenced relative to a first face of a panel, defining at least an edge of a recessed region (107). A side wall extends between the front face and a rear face, the side wall comprising a screw thread (127) for threaded engagement with a corresponding screw thread of the body. The body (1’) comprises a support surface for supporting the body with respect to a panel and an inner wall (103), the inner wall defining an aperture configured for receiving of the insert. The inner wall of the body comprises at least one screw thread on the inner wall (125) for engageably receiving the insert screw thread. The reference surface of the insert is height adjustable with respect to the body by rotating the insert relative to the body. One or more of the reference rims are connected to each other or the insert by frangible connections. When creating apertures in a panel by conventional means weaknesses over time may form leading to joint failure. The disclosed invention provides a support to prevent joint failure.
Patent NZ-729778-A (NZ)
Title: Automated cooking control via enhanced cooking equipment
Inventor: JENKINS JONATHAN
IPC: F24C3/12
Filed: 2015-08-19
Abstract: A control knob comprising a base assembly fixedly secured to a cooking apparatus; a cover rotatably supported by the base assembly; a rotatable drive shaft contained within the control knob and coupled to the cover, the drive shaft being configured to interface with a shaft of a heat source adjustment assembly of the cooking apparatus; and a drive motor contained within the control knob and operatively coupled to the drive shaft to enable, during operation, selective rotation of the shaft of the heat source adjustment assembly in response to cooking adjustment information provided by the cooking control system during the cooking episode.
Patent NZ-729820-A (NZ)
Title: N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway
Inventor: BHAMRA INDER
IPC: C07D401/14
Filed: 2015-10-08
Abstract: This invention relates to compounds of formula (I), in particular compounds of formula (III). More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
Patent NZ-737901-A (NZ)
Title: Anchor, indicator, anchor assembly and fall arrest system
Inventor: PASCOE ANDREW JOHN
IPC: E04G21/32
Filed: 2016-03-03
Abstract: There is disclosed an anchor assembly (10) for coupling a tether (15) to a structure such as a rock wall (14) in a fitted condition with a fastening arrangement (16) having a fastener (23). The anchor assembly (10) includes an anchor body (12) having a first portion (20) located toward a first end (22) adapted to couple with the tether (15) and a second portion (24) located toward a second end (26). The second portion is adapted to receive the fastener in the fitted condition. The anchor assembly (10) also includes an indicator (18) arranged to be engagable in the fitted condition between the fastening arrangement (16) and the anchor body (16). The indicator (18) includes a body portion (41) and a deformable portion (38) extending from the body portion (41), the deformable portion (38) being adapted to be moveable relative to the body portion (41) between an initial non-deformed condition and a deformed condition in response to loading of the fastening arrangement (16). There is also disclosed an anchor system, anchor body and a load indicator as well as a method of use.
Patent NZ-738464-A (NZ)
Title: Crystalline form of the compound (s)-3-{ 4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy} -propane-1,2-diol
Inventor: LESCOP CYRILLE
IPC: C07D413/04
Filed: 2016-05-19
Abstract: The present invention relates to a crystalline form of the compound (S)-3-{ 4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy} -propane-1,2-diol suitable for use in the treatment of diseases/disorders associated with an activated immune system.